Clinical Trial Update: Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial investigating bortezomib and temozolomide for recurrent Grade-4 glioma with unmethylated MGMT promoter (BORTEM-17) is in Phase 1/Phase 2 with s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bortezomib (bortezomib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Haukeland University Hospital | Conditions: Glioblastoma | Phase 1, Phase 2 | Status: UNKNOWN